📰 Biolexa Platform News
Biolexa Platform News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Biolexa Platform. Real-time updates on events, politics, business and more.
May 25, 2023
Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Rating)’s stock price traded up 3.2% on Wednesday . The company traded as high as $1.60 and last traded at $1.60. 55,712 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 577,703 shares. The stock had previously closed at $1.55. Analyst Upgrades […]
May 5, 2023
Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Rating) was up 0.6% during mid-day trading on Tuesday . The company traded as high as $1.78 and last traded at $1.75. Approximately 53,650 shares changed hands during trading, a decline of 92% from the average daily volume of 678,018 shares. The stock had previously closed at $1.74. Analysts […]
April 18, 2023
GH Research (NASDAQ:GHRS – Get Rating) and Hoth Therapeutics (NASDAQ:HOTH – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Earnings and Valuation This table compares GH Research and […]
April 14, 2023
Benchmark reaffirmed their speculative buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Get Rating) in a report issued on Monday morning, Benzinga reports. Benchmark currently has a $5.00 price objective on the stock. Separately, EF Hutton Acquisition Co. I dropped their target price on shares of Hoth Therapeutics from $33.00 to $14.00 and set […]
April 13, 2023
Benchmark reaffirmed their speculative buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Get Rating) in a report published on Monday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. Separately, EF Hutton Acquisition Co. I reduced their price objective on Hoth Therapeutics from $33.00 to $14.00 and set a buy […]
April 6, 2023
Hoth Therapeutics (NASDAQ:HOTH – Get Rating) had its target price cut by EF Hutton Acquisition Co. I from $33.00 to $14.00 in a research note published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Hoth Therapeutics Trading Down 4.3 % Shares of Hoth Therapeutics stock opened at $1.99 on […]
May 21, 2022
Oncorus (NASDAQ:ONCR – Get Rating) and Hoth Therapeutics (NASDAQ:HOTH – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility and Risk Oncorus has a beta of 4.27, meaning […]
March 28, 2022
Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Rating) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 380,700 shares, an increase of 404.2% from the February 28th total of 75,500 shares. Based on an average daily volume of 5,290,000 shares, the short-interest ratio is […]
January 28, 2021
Share this article Share this article NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA), for the treatment of acne. The 1-year agreement extension is based on positive results generat...